I share in your frustration as I am a shareholder too and have been just as affected by the stock trend.
We have no way of knowing what will happen with the stock price. I can tell you that it’s only down now because of the toxic convertible debt that we took last year. We believe that once the conversions are completed and they’ve sold out of their stock (hopefully in the next several weeks) we should see some appreciation in the stock price.
Domestically, we are opening up channels for Nyloxin and expect growing sales throughout the next several quarters. We have also been working with our Pet Pain-Away distributor (DEG) as they have launched the TV and Internet campaign for the product. As for International distribution: we are working with several consultants and have begun the registration process in: Canada, China, Mexica, Spain and Israel. As I stated in my interviews – Nyloxin is already available to be sold in India. We have spoken with several potential new distributors and expect to see the first orders go out later this year.
Lastly, we hired Dr. Dale Vanderputten a few months ago as our new Chief Scientific Officer to take over the clinical development pipeline. His primary efforts are to move forward with RPI-78M under Orphan Designation for the treatment of Pediatric Multiple Sclerosis. We expect to announce the commencement of Phase II clinical trials shortly.
I can tell you that we’re not closing our doors, we’re not going out of business: we will grow sales and exposure for our products which will, eventually, yield some market appreciation.
All said - - - There are a lot of exciting things happening at the Company. Stay posted for additional news.
Yours truly,
Rik
News 
Market Data 
Discover 
AI
